Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBT: 2009-2024

Historic EBT for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$6.5 million.

  • Cumberland Pharmaceuticals' EBT fell 27.39% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year increase of 68.68%. This contributed to the annual value of -$6.5 million for FY2024, which is 2.89% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its EBT stood at -$6.5 million for FY2024, which was down 2.89% from -$6.3 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBT peaked at -$5.6 million during FY2021, and registered a low of -$6.6 million during FY2020.
  • Its 3-year average for EBT is -$6.1 million, with a median of -$6.3 million in 2023.
  • Its EBT has fluctuated over the past 5 years, first increased by 29.29% in 2020, then declined by 12.61% in 2023.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' EBT stood at -$6.6 million in 2020, then grew by 15.34% to -$5.6 million in 2021, then decreased by 0.34% to -$5.6 million in 2022, then dropped by 12.61% to -$6.3 million in 2023, then declined by 2.89% to -$6.5 million in 2024.